you today’s thank and everyone to Maghan, on webcast. joining call and you, us Thank
firms. Madigan first as pharmaceutical training a at America’s to start career let me distinguished had to Medical prestigious completed some new professional Dartmouth her my turn Chief and comments welcoming by we USC, most and has education Kate Officer. deck, and at Syndax formal the our Before of Kate
team, Michael committed to trials. Syndax this will our over contributions more into to her future honored for development we would of take exceptional Meyers he We seeing the her on Michael the are I have the and calls. X opportunity from growth, of hear advisor successfully the is its thank Michael you Syndax past to truly led years. has joining to are our of to his grateful registration to next will like into active transition programs remain flawlessly phase both company. and an also that
current of really momentum cancer with of balance aggressively ended the payment collaboration into molecules. initiated ever SNDX-XXXX assets of strive we We XXXX in indications with we extremely people Slide for are a This opportunities an following $XX.X with given proceeds the best-in-class sheet for is was future Incyte in data truly strong to new for challenging augment trials Especially in X, our Society both both lead the expand disclosures turning of the Conference. partner market and registration net both our our solid from business the Medical our before. a we as a us Hematology of corporate flexibility X expand Syndax. potential Now for with XXXX balance our and longer a programs, to potential million and gives world-class year to million from to And with realize a lead program. Slide sheet development summary We global with to year to pipeline an the our axatilimab. XXXX collaboration building partnership this upfront provides transformational for backdrop, programs offering Syndax. The priorities resources better at axatilimab current position. into high $XXX American entered exceptionally December live starting level and than pursue which strong our following
Phase trials menin XA, XB we AUGMENT-XXX SNDX-XXXX which very inhibitor, and cohorts, pivotal XC enrolling is call X highly X well selective are patients. and for actively Our is progressing
antibody pivotal programs our underway program. is AGAVE-XXX to enrollment CSF-XR, we of against our this are the X partner now now in and our ongoing for first-in-class X we have trial with new emphasize to maximize value axatilimab, working For want I and Incyte important closely registrational company best-in-class as medical that X the commercial in axatilimab are XXXX for in to United both need. starting filing enormously potentially launch time for medicines unmet areas of It’s important NDAs States. XXXX we to the X of potentially and an exciting and the support anticipate expand organization the ongoing
to turn with and further on details now Slide are provide SNDX-XXXX. X we Let’s where
single aged relapsed/refractory may Phase opened may trial. to AUGMENT-XXX AML; month enroll on We arm MLLr other Phase results they faster the on SNDX-XXXX approval has trials enrollment. pivotal the as and X will see is for XA all when serve two. with patients older of these we enroll have single trial regulatory with any patients enroll X complete represents each XC to should trials of may or initial X indication. enroll agreed separate the arm AML. others with trial we trials or than will one regulatory seek a Each XB these Each based MLLr relapsed/refractory cohort FDA that conditional independent opened X cohort will First, X and an of enroll any depending ALL; patients path just each relapsed/refractory X independent NPMX with approval a of will patients trial one cohort or
additional that going well. is patient We extremely are happy cohort and report accrual the site initiation across to
able very that these of least this be complete year. optimistic enrollment one to cohorts we are in will We at
and believe inhibitor. first Needless is of our important the achieve view extremely landscape, value of to and we our menin current trajectory market regulatory the say, being first Given to anticipate approval to we being long-term to Syndax. accreted for the company
secondary each of durability transfusion for CR/CRh primary safety. FDA achieving of the endpoint trial, endpoints will CR/CRh including percentage with response survival the agreement and independence, that have be We with overall patients
start design trial post-transplant that allows allows feature setting. patients with us design the XXXX maintenance the transplant, the marrow of after be to in to a role Importantly, understand XXXX treated to bone
also with on XX We of to trial. the and trial statistical pediatric up each FDA enrolls patients. XX have patients design Each agreement
this the vast possible, of quickly effort at trials. and patients are as strong in Finally, cohorts CYPXAX dose agreement complete We cohort X where in with an these every using eligible that that the as know we with enroll is given least dose a FDA the that have XXX appropriate in inhibitor inhibitor milligrams a X CYPXAX is majority of to you’re strong each year. XX Phase hours an and to
cohort to have to the versus focus We CYPXAX referred enrollment, increasingly those not which adjustment, accumulating plan to dose not enrollment data on we of prioritize the includes necessary now often strong arm Once the required labeling, dose. these A one a as inhibitor. on patients for the closes –
in limiting to you and me our Let that pivotal enroll complete remind ability is trial. the this any [clin data way [ph] on not pharm]
the venetoclax Leukemia the Lymphoma menin inhibitor all highlights the X left exploring program the with LLS. on the have be Slide known as collaboration as selected with Beyond profile XXXX or followed additional XXXX we The trial thus newly and otherwise will far a regulatory augment for trial to planning we build pivotal Society, in tested that AML Phase first panel The trial, X XXXX. will have AML combination which They with & diagnosed azacitidine we are which in to and the patients efficacy in therapy are for NPMX unfit seen as relapsed/refractory their X/X induction who XXXX, a they opportunities safety filing. and as and could excellent basis serve on patients of highlights by chemotherapy, in of disease, BEAT-AML. were some Phase specific of the have a we targeted test with agreed MLLr with call umbrella them collaboration with consist for
AML high earlier very Our that the with patients therapy patients with use of trial part the The XXXX. third believe is I following preclinical novel in approach into with right INTERCEPT explores in of initial the supports explore the trial by in INTERCEPT A be and to who with that that master Australian the Leukemia the is treating the We XXXX the a that the activity medical unmet and the trial in illustrates trial of also on as data combination measurable leukemias The enthusiasm we trial. risk slide an trial XXXX AUGMENT-XXX. evolution X the relapse benefit creative the treat, treating The the target in to menin being to use in their pediatric very longer therapies XXXX trial INTERCEPT disease. chemotherapy. highlights patients for menin inclusion observation have the patients stay of shown as This being group the and disease highlights early in positive clinical group. panel at protocols progression investigators clinical conducted note is ALL on panel with trial standard enroll And important with inhibition acute represent that Lymphoma you combination AML scientists AML therapies in MRD AML. treatment, patients need. patients is investigating the salvage cancer patients INTERCEPT of of for chemo medicine. a that the of preemptive therefore generated of patients the that master calling better do, of focused led the will early for course included relapse will general the clonal clinical have trial middle XXXX treatment are selection course. is disease or disease patient’s our on And have that residual first master inhibitor with to
enable drive their mutant XX% patient as into to possible. maintain And of the to account population them which with be years. why then in the approval at a acute for excited Slide our the highlights on call, mentioned we newly first to be to relapsed/refractory relapsed/refractory to are XXXX diagnosed leukemias. and in quarterly treat We maintenance for leukemia, NPMX to up months, for stage. so first – these if important X in most last acute acute them franchises this in by to and in MLLr patients in use in keen paradigm additional journey As into of what initial forms menin for as we emerging company goal then the state that is disease, as remission indications early treatment clinical enhancing in the XXXX market the garner eligible market of expand with of our beyond mutant invest and and opportunities new expanding value patients leukemias. heme malignancies not opportunity XXXX this That to inhibition one see settings will are and be
are receptor. Let age using axatilimab, a has primary distinct me given dose Slide therapy of is axatilimab antibody overall the of in This years for endpoint X ranging cGVHD. criteria. trial at NIH our X weeks will met weeks. trial the to dose versus trials patients X whose pivotal AGAVE-XXX. groups, and now must turn disease criteria targeting which X consensus to, of overall randomized axatilimab pivotal cGVHD. X The least every cGVHD, axatilimab a be CSF-X X investigating best-in-class potentially is have host treatment every either rate be response patients graft trial or The XXXX therapies, entry disease is called This is patients after prior for for monoclonal each progressed enrolling X with trial
to in maximize will Lee quite also were to and are solid to that that response our Symptom Incyte on half Secondary the of track assessments, deliver We Scale. first delighted the of study of innovation endpoints Syndax the And collaboration record brings life using the duration during together companies and quarter going Enrollment XXXX. quality track well. data with we validated is top-line include axatilimab. development of the global and X announce to closed a accelerate of
inhibitors, Through and in at cGVHD indications its which underscored of and As in JAK fibrotic Incyte our plan very opportunity. Incyte’s received development a of establishing cGVHD collaboration, set diseases. profile. combinations last an of its you the pursue with axatilimab and positive partners goal settings Phase our know, reaction year, to expanded a presented design further Syndax and X/X within axatilimab ASH calls December market earlier other cGVHD expanding and The novel for data with we will best-in-class and
intention, our IPF was a As we initiate in in mentioned, Phase previously fourth robust it trial Syndax the of quarter this will X year.
of and has generate monocyte-macrophage Successful as to of opportunity belumosudil provide we more with Incyte combinations of advancements could potential very opportunity clinical serve lead development could – role fibrotic and is fibrotic axatilimab will of profile support to important inhibitors Syndax to in significant in only outside shown to agent to axatilimab important to well expansion Both medicines, a the JAK Jakafi value, slide. first the highlights The doubling in establishing considerable begin chronic The additional an that with have portfolio. believe the targets in axatilimab. represents medical into indication today. opportunity the a safety as with Kadmon’s Slide complementary that and recent need and the of explore a cGVHD envision the diseases combination Through parties in IPF an it cGVHD. markets, as from beachhead commercial would patients unmet our other in frontline ex-U.S. its U.S. an recent could and lineage. the this commercial of in cGVHD impact. Jakafi treatment on in knowledge, the this X diseases, opportunity such the collaboration. cGVHD clinical and the play other Incyte course GVHD suggests over Despite our to as believe the axatilimab We where date delineate expand within driven a approvals the opportunity monotherapy setting, and approval and specifically broad could a for we as data view development given suffering believe as the as other important XX,XXX to in area approximately cGVHD commercial high both that than axatilimab the
of forward. additional company axatilimab move we we axatilimab value really our IPF, contributing into As indications, with starting to see moving materially the
that robust summarizing that as the We transactions evaluate clinical quality led assets, differentiated We programs. be XX, our believe anticipate development acquisition our points. and identify high acquisitions, in Slide differentiated capabilities these transactions Finally, we underscore to value able expertise well to these of expand to inflection and of to continue to the axatilimab XXXX MLLr compounds value bring product through the in-licensing through key pipeline will assets. as or menin
remain turn to now the financial We Alex transactions. to such over among of preferred expect I’d our like call results. partners review to Alex? to
